Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.

guest :: login DKFZ
		Search		Submit		Personalize Your alerts Your baskets Your searches		Help

Home > Publications database > Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial. > Access to Fulltext

Information
Files

Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial. - DKFZ-2024-00262

Main document file(s):

Similar records

DKFZ :: :: :: ::
Powered by v1.1.7 |
Maintained by

Impressum | Data Privacy Policy